Ercanetide

Ercanetide (NNZ 2591) is a synthetic analogue of a small peptide of cyclic glycine proline (cGP) . Ercanetide shows orally active and cross the blood-brain barrier. Ercanetide shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. Ercanetide has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3].

Product Specifications

CAS Number

[847952-38-9]

Product Name Alternative

NNZ-2591

UNSPSC

12352209

Target

Biochemical Assay Reagents

Type

Peptides

Related Pathways

Others

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nnz-2591.html

Purity

99.98

Solubility

DMSO : 18.75 mg/mL (ultrasonic)

Smiles

C=CC[C@@]12N(CCC2)C(CNC1=O)=O

Molecular Formula

C10H14N2O2

Molecular Weight

194.23

References & Citations

[1]Guan J, et al. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010 Jul 11;210 (2) :221-8.|[2]Guan J, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology. 2007 Nov;53 (6) :749-62.|[3]Copping NA, et al. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome. Neurotherapeutics. 2021 Jul;18 (3) :1535-1547.